Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 1:19 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1345–1368 of 2,669 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Control II Clear all
Completed Phase 2 Interventional Results available

Trial of Oral Valproic Acid for Retinitis Pigmentosa

NCT01233609
View directory record Official record
Conditions
Retinitis Pigmentosa
Interventions
Valproic Acid, Placebo
Drug
Lead sponsor
Foundation Fighting Blindness
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
6
States / cities
Miami, Florida • Ann Arbor, Michigan • Portland, Oregon + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2017 · Synced Oct 31, 2026, 1:19 PM EDT
Completed Phase 2 Interventional Results available

Evaluation of the Efficacy and Safety of Peramivir in Subjects With Uncomplicated Acute Influenza.

NCT00419263
View directory record Official record
Conditions
Influenza
Interventions
Peramivir 150 mg, Peramivir 300 mg, Placebo
Drug
Lead sponsor
BioCryst Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
344 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
58
States / cities
Birmingham, Alabama • Jonesboro, Arkansas • Anaheim, California + 45 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2015 · Synced Oct 31, 2026, 1:19 PM EDT
Completed Early Phase 1 Interventional

Ketoconazole in Treating Participants With Ongoing EGFR Inhibitor-Induced Rash

NCT03471364
View directory record Official record
Conditions
Malignant Neoplasm
Interventions
Ketoconazole, Laboratory Biomarker Analysis, Placebo Administration, Quality-of-Life Assessment, Questionnaire Administration
Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
6
States / cities
Danville, Illinois • Urbana, Illinois • Rochester, Minnesota + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 31, 2026, 1:19 PM EDT
Completed Not applicable Interventional Results available

Memory and Attention Adaptation Training-Geriatrics (MAAT-G) Phase II

NCT04669301
View directory record Official record
Conditions
Cancer-related Problem/Condition, Cognitive Impairment
Interventions
MAAT-G, Supportive therapy (time and attention control)
Behavioral
Lead sponsor
University of Rochester
Other
Eligibility
65 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jul 15, 2025 · Synced Oct 31, 2026, 1:19 PM EDT
Terminated Phase 2 Interventional Results available

A Study of Topical Steroids as Preemptive Therapy for EGFR Inhibitor-Induced Papulopustular Eruption

NCT03115567
View directory record Official record
Conditions
Acneiform Rash, Papulopustular Eruption
Interventions
Triamcinolone
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 17, 2023 · Synced Oct 31, 2026, 1:19 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Thyroid Eye Disease

NCT06106828
View directory record Official record
Conditions
Thyroid Eye Disease
Interventions
Satralizumab, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
6
States / cities
San Diego, California • Danbury, Connecticut • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 31, 2026, 1:19 PM EDT
Terminated Phase 2 Interventional Results available

This Study Tests Whether BI 409306 Prevents Patients With Schizophrenia From Becoming Worse. This Study Looks at How Well Patients Tolerate BI 409306 and How Effective it is Over 6 Months

NCT03351244
View directory record Official record
Conditions
Schizophrenia
Interventions
BI 409306, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 55 Years
Enrollment
264 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
32
States / cities
Phoenix, Arizona • Costa Mesa, California • Garden Grove, California + 27 more
Source: ClinicalTrials.gov public record
Updated May 14, 2025 · Synced Oct 31, 2026, 1:19 PM EDT
Completed Phase 2 Interventional Results available

Study of the Clinical Effectiveness of a Human Monoclonal Antibody to C. Difficile Toxin A and Toxin B in Patients With Clostridium Difficile Associated Disease

NCT00350298
View directory record Official record
Conditions
Clostridium Infections
Interventions
GS-CDA1/MDX-1388, normal saline
Biological
Lead sponsor
MassBiologics
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
22
States / cities
Los Angeles, California • Oakland, California • Newark, Delaware + 18 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2021 · Synced Oct 31, 2026, 1:19 PM EDT
Active, not recruiting Phase 2 Interventional

Study of Aspirin in Patients With Vestibular Schwannoma

NCT03079999
View directory record Official record
Conditions
Vestibular Schwannoma, Acoustic Neuroma, Neurofibromatosis 2
Interventions
Aspirin, Placebo
Drug
Lead sponsor
Massachusetts Eye and Ear Infirmary
Other
Eligibility
12 Years and older
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2029
U.S. locations
5
States / cities
Stanford, California • Miami, Florida • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 31, 2026, 1:19 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Vaccination of Triple Negative Breast Cancer Patients

NCT02938442
View directory record Official record
Conditions
Triple Negative Breast Cancer, Breast Neoplasms
Interventions
P10s-PADRE with MONTANIDE™ ISA 51 VG, Doxorubicin, Cyclophosphamide, Paclitaxel
Biological · Drug
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years and older · Female only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
2
States / cities
Fayetteville, Arkansas • Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Nov 7, 2024 · Synced Oct 31, 2026, 1:19 PM EDT
Active, not recruiting Phase 2 Interventional

A Phase 2 Study of YA-101 in Patients With Multiple System Atrophy

NCT06848231
View directory record Official record
Conditions
Multiple System Atrophy
Interventions
YA-101, Placebo
Drug
Lead sponsor
Dasher Neuroscience Inc.
Industry
Eligibility
30 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
6
States / cities
Los Angeles, California • Boston, Massachusetts • Rochester, Minnesota + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 31, 2026, 1:19 PM EDT
Completed Phase 2 Interventional

Study Evaluating the Safety and Efficacy of MEGF0444A in Combination With Carboplatin, Paclitaxel and Bevacizumab in Patients With Advanced or Recurrent Non-Squamous Non-Small Cell Lung Cancer Who Have Not Received Prior Chemotherapy for Advanced Disease (NILE)

NCT01366131
View directory record Official record
Conditions
Non-Squamous Non-Small Cell Lung Cancer
Interventions
MEGF0444A, bevacizumab, carboplatin, paclitaxel, placebo
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2011
U.S. locations
20
States / cities
Birmingham, Alabama • Hot Springs, Arkansas • Santa Monica, California + 17 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Oct 31, 2026, 1:19 PM EDT
Completed Phase 2 Interventional Results available

Study Evaluating Intepirdine (RVT-101) on Gait and Balance in Subjects With Dementia

NCT02910102
View directory record Official record
Conditions
Alzheimer's Disease, Dementia With Lewy Bodies, Parkinson's Disease Dementia
Interventions
RVT-101 35 mg, Placebo
Drug
Lead sponsor
Axovant Sciences Ltd.
Industry
Eligibility
50 Years to 89 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
11
States / cities
Phoenix, Arizona • Simi Valley, California • Temecula, California + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2020 · Synced Oct 31, 2026, 1:19 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Genetic Counseling Patient Preference Intervention Versus Conventional Genetic Counseling for Women at Elevated Risk for Breast Cancer

NCT05325151
View directory record Official record
Conditions
Breast Carcinoma
Interventions
Educational Intervention, Genetic Counseling, Survey Administration
Other
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
30 Years to 64 Years · Female only
Enrollment
874 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Oct 31, 2026, 1:19 PM EDT
Completed Phase 2 Interventional

Safety and Effectiveness of the Selegiline "Patch" for Decreased Mental Function in HIV Patients

NCT00013585
View directory record Official record
Conditions
Cognition Disorders, HIV Infections
Interventions
Selegiline hydrochloride
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2005
U.S. locations
15
States / cities
Los Angeles, California • San Diego, California • Honolulu, Hawaii + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Oct 31, 2026, 1:19 PM EDT
Completed Phase 2 Interventional Results available

Minocycline Hydrochloride in Reducing Chemotherapy Induced Depression and Anxiety in Patients With Stage I-III Breast Cancer

NCT02203552
View directory record Official record
Conditions
Anxiety Disorder, Depression, Recurrent Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
Interventions
minocycline hydrochloride, placebo, laboratory biomarker analysis, Questionnaire administration
Drug · Other
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 8, 2025 · Synced Oct 31, 2026, 1:19 PM EDT
Active, not recruiting Phase 2 Interventional

A Study to Test Different Doses of BI 1584862 in People With a Distinct Form of Age-related Macular Degeneration (AMD) Called Geographic Atrophy

NCT06769048
View directory record Official record
Conditions
Geographic Atrophy
Interventions
Placebo-matching BI 1584862, BI 1584862
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
50 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
43
States / cities
Gilbert, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 38 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 31, 2026, 1:19 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Safety and Effectiveness of Kovacaine Nasal Spray for Dental Anesthesia

NCT01302483
View directory record Official record
Conditions
Dental Anesthesia Efficacy
Interventions
3% tetracaine HCL with 0.05% oxymetazoline HCL, Lidocaine Injection
Drug
Lead sponsor
St. Renatus, LLC
Industry
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jun 17, 2015 · Synced Oct 31, 2026, 1:19 PM EDT
Withdrawn Phase 2 Interventional

OTI-010 for Graft-Versus-Host Disease Prophylaxis in Treating Patients Who Are Undergoing Donor Peripheral Stem Cell Transplantation for Hematologic Malignancies

NCT00081055
View directory record Official record
Conditions
Graft Versus Host Disease, Leukemia, Myelodysplastic Syndromes
Interventions
autologous expanded mesenchymal stem cells OTI-010, busulfan, cyclophosphamide, cyclosporine, methotrexate, peripheral blood stem cell transplantation, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
Mesoblast International Sàrl
Industry
Eligibility
18 Years to 55 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 4, 2014 · Synced Oct 31, 2026, 1:19 PM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

A 20-Week Study of a New Treatment for Men With Benign Prostatic Hyperplasia (BPH).

NCT00044226
View directory record Official record
Conditions
Prostatic Hyperplasia
Interventions
ML-04A
Drug
Lead sponsor
Milkhaus Laboratory
Industry
Eligibility
45 Years to 80 Years · Male only
Enrollment
350 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002
U.S. locations
14
States / cities
Mobile, Alabama • Fair Oaks, California • Stanford, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 31, 2026, 1:19 PM EDT
Completed Phase 4 Interventional Results available

The END Perioperative Smoking Pilot Study

NCT02482233
View directory record Official record
Conditions
Smoking, Nicotine Addiction, Surgery
Interventions
ENDD (NJOY), NRT (NicoDerm CQ), telephone counseling, brief advice, brochure
Behavioral · Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 9, 2022 · Synced Oct 31, 2026, 1:19 PM EDT
Completed Phase 3 Interventional

HKT-500 in Adult Patients With Ankle Sprain

NCT00680784
View directory record Official record
Conditions
Ankle Sprain
Interventions
HKT-500 Ketoprofen Topical Patch, Placebo Patch
Drug · Other
Lead sponsor
Hisamitsu Pharmaceutical Co., Inc.
Industry
Eligibility
18 Years and older
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
30
States / cities
Birmingham, Alabama • Montgomery, Alabama • Anaheim, California + 26 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2015 · Synced Oct 31, 2026, 1:19 PM EDT
Terminated Phase 2 Interventional

A Study Comparing the Safety and Effectiveness of Cartilage Cell Injected Into the Lumbar Disc as Compared to a Placebo

NCT01771471
View directory record Official record
Conditions
Degenerative Disc Disease
Interventions
NuQu, Placebo
Biological · Other
Lead sponsor
ISTO Technologies, Inc.
Industry
Eligibility
21 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
10
States / cities
Birmingham, Alabama • San Francisco, California • Santa Monica, California + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2017 · Synced Oct 31, 2026, 1:19 PM EDT
Recruiting Not applicable Interventional

Auricular Acupressure in Prehabilitation

NCT06516198
View directory record Official record
Conditions
Frailty, Thoracic, Prehabilitation, Lung Surgery, Wedge Resection, Segmentectomy, Lobectomy, Pneumonectomy; Status
Interventions
Auricular Acupressure
Other
Lead sponsor
University of Chicago
Other
Eligibility
50 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 9, 2025 · Synced Oct 31, 2026, 1:19 PM EDT